Moxifloxacin's gathering and adding competitors Bayer and dongyangyao

On January 8, Huabang Health announced that Chongqing Huabang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Chongqing Huabang Pharmaceutical Co., Ltd., had recently obtained the drug registration approval document of moxifloxacin hydrochloride tablets approved and issued by the State Food and drug administration It is reported that the product has been included in the catalogue of Chinese listed drugs (generic drugs approved according to the new registration classification of chemical drugs), which is deemed to have passed the consistency evaluation and is expected to participate in the second batch of volume purchase Bid for more than 270 million yuan Table 1: basic information of drug registration approval Source: company announcement Figure 1: Sales of moxifloxacin hydrochloride tablets in public medical institutions in China (unit: 10000 yuan) Source: the terminal competition pattern of Chinese public medical institutions in the Internet It is reported that moxifloxacin hydrochloride belongs to the fourth generation of broad-spectrum fluoroquinolones Compared with the previous three generations of anti infective drugs, moxifloxacin hydrochloride has stronger antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria and other common pathogens, and has the advantages of high safety and low resistance rate Moxifloxacin hydrochloride is mainly used to treat adults with upper and lower respiratory tract infections (such as community-acquired pneumonia, acute sinusitis, acute attack of chronic bronchitis), as well as skin and soft tissue infections At the terminals of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions for short), the sales of moxifloxacin hydrochloride tablets increased steadily, reaching nearly 800 million yuan in 2018 At present, Bayer is the leading enterprise in the market, with a market share of 99.85% Figure 2: moxifloxacin hydrochloride tablets previously evaluated